P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL

• Aaron T. Gerds,
• Michael Grunwald,
• Stephen Oh,
• Evan Braunstein,
• Zhenyi Xue,
• Valkal Bhatt,
• Jingbo Yu,
• Ruben Mesa

Affiliations

Aaron T. Gerds

1 Cleveland Clinic Taussig Cancer Institute

Michael Grunwald

2 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health

Stephen Oh

3 Washington University School of Medicine

Evan Braunstein

4 Incyte Corporation

Zhenyi Xue

4 Incyte Corporation

Valkal Bhatt

4 Incyte Corporation

Jingbo Yu

4 Incyte Corporation

Ruben Mesa

5 UT Health San Antonio MD Anderson Cancer Center